Next Biosciences Expands Reproductive Health Services Amid Rising Infertility in SA
Next Biosciences, a leader in reproductive health, has broadened its services to support individuals and couples across the country. The company now offers a range of advanced solutions, including carrier screening, endometrial health testing, and the MiniMi fetal sex test. Ashleigh Bouguenon, Head of Reproductive Health at Next Biosciences, shares more insights:
Sound Bite - Reproductive Health_ Next Biosciences
The global FemTech sector, valued at approximately R750 billion in 2024, is projected to reach R1.86 trillion by 2030, with fertility services playing a major role in this growth. The fertility market alone is expected to nearly double, reaching an estimated R793 billion by 2026. Among its offerings, Next Biosciences now provides Non-Invasive Prenatal Testing (NIPT), which presents a safer alternative to traditional invasive procedures. As February marks Reproductive Health Month, the focus is on empowering individuals with the knowledge and options necessary to take charge of their reproductive care.
